EA003414B1 - Neuro-immune-endocrine regulating device and treatment - Google Patents

Abstract

1. A method for treating neuro-immune-endocrine dysfunction comprising photostimulating an orbital area of the cerebral cortex consecutively via at least three contiguous sites of each orbtial roof using light peaking at 350-400 nm and 750-800 nm for at least 2 per site. 2. A method as claimed in claim 1 wherein the medical conditions that are treatable include the following: allergies (especially respiratory), immunodeficiency, cancer, systemic lupus erythernatosus, eczema, psoriasis, thyroid disease, viral syndromes, pathologies involving neuro-immune-endocrine dysfunction, essential hypertension, chronic pharyngitis, rheumatoid arthritis. 3. A medical device as claimed in claim 1 comprising means for providing light, said means provides light peaking at 350-400 nm and 750-800 nm. 4. A medical device as claimed in claim 3, wherein the means for providing light comprises a low-powered light source. 5. A medical device as claimed in claim4, wherein the light source is a lowpowered medical bulb. 6. A medical device as claimed in any one of claims 1 to 3, wherein the means for providing light comprises at least two lens-holders, each with a quartz glass and a lens. 7. A medical device as claimed in claim 6, wherein the means for providing light comprises a filter in front of each lens operable to transmit light peaking at 350- 400nm and 750-800 nm. 8. A medical device as claimed in claim 7, wherein the filter is provided with a diffuser. 9. A medical device as claimed in any one of claims 1 to 6 further comprising an output regulator for varying the voltage/current supplied to the means for providing light and a display for displaying the output voltage/current supplied. 10. A medical device as claimed in claim 7 and provided with programmable functions.

Description

The present invention relates to medicine, and in particular includes a device and method of treatment based on the application of the principles of photobiology in the field of neuroimmuno-endocrinology. The invention is intended for the treatment of neuro-immuno-endocrine disorders by photostimulation of pigmented neurons in the orbital region of the cerebral cortex by filtered light. It is known that there are direct afferent and efferent pathways between the orbital region of the cerebral cortex and the hypothalamus. The hypothalamic-pituitary-adrenal axis and the axis of the brain-bone marrow play a central role in neuro-immuno-endocrine regulation. The experiments performed by the applicant showed that the method of photostimulation of the orbital region of the cerebral cortex using the developed device causes modulation of the hypothalamic-pituitary-adrenal axis and / or the axis of the brain-bone marrow (possibly some other axes), which is crucial for the treatment of the following pathologies: hypertension , chronic pharyngitis, rheumatoid arthritis, allergies (especially respiratory), immunodeficiency of any etiology, cancer, systemic lupus erythematosus, eczema, psoriasis, thyroid diseases lezy, viral syndromes and other pathologies associated with the neuro-immuno-endocrine disorders.

The positive results obtained in the treatment of most of the above diseases using traditional pharmacological therapy, as a rule, do not always exceed the risk to the patient. The device proposed by the applicant applies only filtered light and no medication. Treatment with the device does not cause pain, does not require surgery and is not toxic.

State of the art

In the patent EB-A-2 746 321 a device for treatment without surgery, chemotherapy or radiotherapy of (autoimmune) pathologies associated with immunological disorders is presented. The device includes a means for light emission and filters for blocking UV and IR radiation.

The device was tested in preliminary experiments for 2 months. Its effectiveness turned out to be very insignificant. Clinical improvement was negligible and lasted no more than 1 week.

SUMMARY OF THE INVENTION

The device has optical and electronic components with the following (but not limited to) characteristics. All technical specifications of this device are provided below for the purpose of illustration and not limitation.

In the manual model, the optical components include 2 lenses made of plastic or other light material (cylindrical or other shape). Each lens has quartz glass (diameter about 9 mm, thickness 1.1 mm) at one end and a biconvex lens (at least 50 diopters; diameter about 9 mm, thickness 3 mm; or with other specifications suitable for photostimulation of the orbital region of the cortex brain) located at the corresponding focal length inside. Before each biconvex lens there is a filter with or without diffuser (diameter about 9 mm, thickness 1 mm), transmitting light with a wavelength of 350-400 nm and 750-800 nm (or with other wavelengths suitable for photostimulation of the orbital region of the head cortex brain). Behind each lens, near the base of each of the lenses, is placed a medical light bulb of low power (2.7-4 V) or a light source of similar power.

In the manual model of the device, both lenses are built into a rectangular plastic case (approximately 132x170 mm) containing a printed circuit, a cell for the battery (for the battery model) and an articulated mechanism for pointing the lenses at various points on the upper wall of the eye sockets. Powered by DC 6 V (battery model) or 220 V (network model), and the output - 0.5-3 V DC (variable), 50-300 mA. The device is equipped with an output power regulator and a digital indicator showing the voltage or mA.

A stationary model of the device is planned, which will include computer boards with craniometric, densitometric and other programmable functions.

The treatment method consists in superimposing the ends of the lenses sequentially on 3 or more adjacent points of each of the upper wall of the orbits for 2-4 minutes per point. This treatment is carried out 2 times a week for up to 2 months. Given the pathology and condition of the patient, if necessary, such treatment can be repeated. Patients are treated in a lying (or sitting) position, with their eyes closed. It should be emphasized that the effect is not directed to the eyes; in other words, light does not pass through the retina. The upper wall of the orbit is selected as the entry point for photostimulation, since it consists of a thin translucent layer of bone tissue.

In the light of practical experience with the present invention, the following instructions are of particular importance:

for the convenience of treatment, the weight of the manual model of the device (including batteries) should not exceed 500 g;

lenses can be made from a variety of lightweight materials, but non-conductive material such as hard plastic is recommended;

the ends of the lenses should be smooth enough so as not to cause scratches or irritation of the upper wall of the orbits;

the thickness of the filters can be up to 2 mm, however, to facilitate the passage of light, preferably the thickness is 1 mm;

to reduce internal reflection, the surface of the filters on the side of the light source must have a diffuser;

lenses with different characteristics can be used, but they must be biconvex with a power of 50 to 100 diopters;

recommended coating for lenses and quartz glasses;

treatment should be carried out in soft lighting (a low-power non-halogen lamp with a lampshade should be used, fluorescent lamps should be avoided);

treatment of patients can be carried out in a sitting position, but preferably lying position, as it helps to relax;

exposure to the orbital point should last at least 2 minutes, preferably 3-4 minutes, which is especially effective in most cases;

it is preferable to conduct two sessions per week, which provides the best result;

usually the initial treatment period is 2 months.

Advantages of the Invention

Given what components are required, the production of this medical device should be relatively cheap.

Optical and electronic parts can be produced independently, and their assembly is not difficult. An optical company, for example, can conclude a contract for the electronic part of the device (or vice versa).

With the widespread use of the device, industry will be able to produce more advanced models based on the principles and specifications outlined in the previous sections. For example, an improved stationary model can be used in conjunction with units for brain tomography, EEG and other neurological equipment.

Since very short sessions are used for treatment, the cost of treatment for the patient and the operating costs for the specialist physician are very small.

It should be emphasized that all the technical specifications for this device, throughout the document, are given for the purpose of illustration, and not limitation.

Information confirming the possibility of carrying out the invention

Neuro-immuno-endocrine regulation and treatment: cortical photostimulation

A device for the regulation and treatment of neuro-immuno-endocrine disorders according to the invention provides periodic light irritation of the orbital region of the cerebral cortex through the upper walls of the orbits. According to the name of the photostimulated area, the authors called this effect cortical photostimulation.

Over 110 patients with various pathologies of the immune and / or immuno-endocrine system were treated with the method according to the invention

Treatment of pathologies from September 1996 to September 2000

Serological and clinical results General observations

The results steadily observed in clinical trials on cortical photostimulation were an increase in the number of CE4 + and T cells, a decrease in the number of CE8 and a corresponding increase in the ratio of CO4 / CO8. In a preliminary experiment on 8 HIV-negative patients (3 men, 5 women aged 23-68 years), the ratio of CE4 / SE8 increased by 25% (from 2.02 to 2.54) after 1 session of cortical photostimulation (i.e. in 7 days). In a double-blind clinical test involving 31 patients with autoimmune pathologies that are serologically negative for HIV, an increase in SE4 by 11.77% (p = 0.01), a decrease in SE8 by 11.32% (p = 0.00100733), and an increase in the ratio ί.Ό4 / ί.Ό8 by 26.19% (p = 0.00000363, Student ΐ-test) after 2 sessions of cortical photostimulation (that is, for 18-19 days).

In a clinical trial involving 10 AIDS-HIV patients, the average increase in the percentage of CE4 + T cells over an average of 22.7 days (3 weekly sessions of cortical photostimulation) was 605.4% (p <0.00005, bilateral Student's 1 criterion). The ί.Ό4 / ί.Ό8 ratio increased on average by 575.65% (AIDS) and 125.26% (HIV).

In patients sero-negative for HIV and subjected to cortical photostimulation for at least 1 month, treatment, in addition, prevented influenza and other (seasonal) infections. Cessation of chronic pharyngitis (and / or palatine tonsil infections), acne, hemorrhoids, and baldness has also often been observed.

HIV seropositive patients showed marked improvement and / or cessation of opportunistic infections, including oropharyngeal candidiasis, oral herpes, hepatitis C, pneumonia caused by Rheitosuccb sappi, and bronchitis at week 4 of cortical photostimulation.

In general, patients reported that they feel rested, energetic, and sleep better.

Side effects were not observed and there were no reports of them for 4 years (September 1996 - September 2000). Under no circumstances did the attending physician require patients to stop taking the medicine. Each patient made a decision to stop taking the medicine independently. In most cases, this decision coincided with the cessation of symptoms.

I. Autoimmune pathologies

1. Allergies

Allergies of the upper and lower respiratory tract of patients (5 men and 15 women aged 14-61 years) with a long history of allergic rhinitis, with symptoms of sneezing, itching, watery discharge, stuffy nose and constipation. 18 of them showed a marked improvement in symptoms after 1 week of cortical photostimulation. In 3 patients with asthma, symptoms (cough, airway spasms) began to decrease after 2 weeks of cortical photostimulation. In 2 patients (30 and 57 years old) no improvement was observed. In another case (61 years), the improvement lasted 3 months.

Skin allergies of patients (1 man and 4 women aged 19, 30, 32, 61 and 64 years old, respectively) with allergic contact dermatitis (swelling, sensation of heat, itching, redness and soreness). 4 of them showed no allergic symptoms after 2 weeks of cortical photostimulation. The 32-year-old patient had some improvement.

2. Systemic lupus erythematosus (SV) of a patient (24, 28, and 56 years old) with a long history of SV. After 2-3 weeks of cortical photostimulation, a marked decrease in the titers of anti-DNA and ΑΝΡ antibodies was observed. Renal function improved significantly (creatinine clearance; decreased amount of protein in the urine).

patient (43 years old), sero-negative for anti-DNA and ΑΝΡ, but with a long history of SV. After 3 weeks of treatment, the black bands on the nose and cheeks disappeared.

3. Hypothyroidism A patient (64 years old) with a 9-year history of hypothyroidism (hyperbetacarotenemia, hypercholesterolemia, enlarged thyroid gland, dry skin). After 3 weeks of cortical photostimulation, a marked improvement was observed. Yellow pigmentation disappeared, cholesterol levels, T3 and T4 returned to normal. Repeated symptoms did not appear for more than 3 years.

a patient (31 years old) with a 4-year history of hypothyroidism (enlarged thyroid gland, emaciation, tachycardia, low blood pressure, asthenia) who received hormone therapy (T4). After 2 sessions of cortical photostimulation, a clear clinical improvement was observed: asthenia stopped, tachycardia decreased, and blood pressure stabilized. 3 weeks after the start of treatment, a decrease in the size of the thyroid gland was revealed.

4. Psoriasis of the patient (girl 10 years old, man 35 years old and man 56 years old) underwent cortical photostimulation for only 6 weeks, but the disease did not resume within 1.5-2 years.

A girl with a 7-year history of psoriasis, with symptoms of rash, itching, and peeling on the head, armpits, and stomach. After 1 week after the first session of cortical photostimulation, scabies stopped, and after 3 weeks a rash on the head passed. A recovery of approximately 80% was observed, which lasted more than 2 years.

A 35-year-old man with a 10-year history of psoriasis, with symptoms of a rash on his forehead, head, and neck. 2 weeks after the start of cortical photostimulation, improvement was observed. Recovery (70%) lasted a year and a half.

A 56-year-old man with an 11-year history of psoriasis, with symptoms of rash and itching on the head and right leg; severe ulceration on the leg. 2 weeks after the first session of cortical photostimulation, an improvement was observed. The ulcers healed. Repeated symptoms appeared after 3 years.

5. Atopic eczema of a patient aged 30, 42, and 63 years.

A 30-year-old woman with a 25-year history of eczema on both legs, with symptoms of severe flaking and ulceration, took only 6 weeks of weekly cortical stimulation sessions. Full recovery on the 4th week of treatment. Eczema appeared again after 6 months.

A 42-year-old woman with a 30-year history of eczema on both hands, with symptoms of itching, peeling and ulceration in winter and spring, received cortical photostimulation for 3 years. Symptoms ceased (with the exception of one mild relapse — 5% — lasting 3 weeks).

A 63-year-old woman with a 10-year history of eczema on her left leg, with symptoms of itching (especially when wearing a sock and at night in bed), peeling and ulceration, received cortical stimulation for 3 months. An improvement of 80% was observed. The leg has healed.

6. Uveitis and childhood rheumatoid arthritis (DRA)

A boy of 5 years with a 3-year history of DRA and uveitis. Oligoarticular form of arthritis (left knee and lower leg, proximal interphalangeal joints of the right index finger), uveitis of both eyes and cataract of the right eye. Received cortical photostimulation for 7 months. The acute phase of uveitis has passed. Several mild episodes of inflammation in the right knee that have gone away in a few hours. Parents reported a noticeable positive change in the temperament of the child.

7. Rheumatoid arthritis (RA)

Ί

1) Double-blind, randomized clinical trial for RA involving 7 patients: see below.

2) 10 patients (9 women and 1 man aged 35-68 years) received cortical photostimulation for 4 weeks, while RF titers (rheumatoid factor) and inflammation and pain during movement decreased markedly. Clinical improvement after 2 weeks of cortical photostimulation.

3) Long-term treatment and observation: 3 patients - 2 women, 1 man (see below).

II. Immunodeficiency (HIV and AIDS)

1) A clinical trial of AIDS-HIV involving 8 AIDS patients and 2 HIV patients (see above). See below for more information.

2) In 8 AIDS patients (2 women and 6 men aged 2-35 years), there was a noticeable clinical improvement after 1-2 weeks of cortical photostimulation. As with the 10 AIDS-HIV test subjects discussed above, all patients reported anorexia, fever, cessation of peripheral neuropathy, acne, blackout, and generalized lymphadenopathy. Many patients gained 5-15 kg in weight over 3-6 weeks.

III. Viral syndromes

Hepatitis C

1) 1 patient 56 years old. Gradual decrease in hepatic enzymes: normal or near normal values of LIN, COT, ORT, Υ-CT, alkaline phosphatase, bilirubin, 5'-nucleotidase after 6-7 months of cortical photostimulation (see below).

2) Close to 1) the results were observed in patient No. 8 (male 28 years old) from the AIDS-HIV clinical trial, namely, a noticeable decrease in COT, CPT, alkaline phosphatase and bilirubin within 22 days. See below for more information.

Patient Epstein-Barr virus syndrome (women 38, 42, 43 and 50 years old) with a long history of joint pain, mild fever, recurrent urinary tract infections, sore throat, skin rash, fatigue and seropositive reaction to Epstein-Barr ^ C. A marked improvement in symptoms was noted after 2–3 weeks of cortical photostimulation.

IV. Cancer

1) Acute lymphoblastoma leukemia (see below).

2) Prostate adenocarcinoma

The man is 65 years old. Prostate adenocarcinoma was detected in 1994, then surgery and hormone therapy were performed. The disease resumed at the end of 1996 with symptoms of pain in the lower abdomen and polyuria. Cancer marker P8A: 300 ng / ml (21/11/96). Decreased to 130 ng / ml (11/12/96) after 2 sessions of cortical photostimulation (for 19 days), stabilized at 150 ng / ml after a further 6 sessions of cortical photostimulation (13/01/97). The patient stopped cortical photostimulation in January 1997 and died in May 1998.

The man is 76 years old. Prostate adenocarcinoma was detected in November 1999. Neither surgery nor chemotherapy was performed. He received cortical photostimulation from November 1999 to September 2000 (2-3 sessions per week) with a very good result: a low level of the cancer marker P8A (5.2 ng / ml) and no pain.

V. Osteoarthritis (OA) of patients (40, 50, 53, 57, and 58 years old) with a long history of OA of the knees, hips, arms, and legs. 4 of them showed a marked improvement in inflammation, pain and stiffness after 2 weeks of cortical photostimulation. No improvement was observed only in a woman of 57 years.

VI. The patient’s hypertension (1 woman 70 years old, 3 men aged 42, 57 and 76 years) with a long history of hypertension, received cortical photostimulation for 3 weeks. Pressure 160, 160, 160, 150 (systolic) and 100, 90, 90 and 80 (diastolic), decreased to 120/60, 130/64, 130/65 and 130/60, respectively, 2 weeks after the start of cortical photostimulation .

VII. Chronic pharyngitis of a patient (3 women aged 42, 42 and 64 years and 1 man 68 years) with chronic pharyngitis received cortical photostimulation for 3 weeks, 8 weeks, 2.5 years and 3 weeks, respectively. Chronic inflammation, redness of the throat and continuous pain began to disappear 2 weeks after the start of treatment. Palatine tonsil infection (in 3 patients) did not recur for 2 years.

Viii. Diabetes of a patient I (1 woman 20 years old and 2 men 27 and 39 years old) with a 10-, 15- and 28-year history of diabetes, respectively, all regularly received treatment with insulin. No significant change in symptoms was observed, but the first 2 patients noted a cessation of polyuria.

Double-blind, randomized clinical trial of I subpopulation of lymphocytes in autoimmune diseases

Methods

31 people (16 men and 15 women aged 10-73 years) were selected from Tucuman (Argentina) to participate in a double-blind cortical photostimulation test. The test was carried out in accordance with local bioethics requirements. All volunteers gave written consent. Of the total number of patients, 20 were assigned to the active group, and 11 to the control group using a random number table. 18 participants suffered from various autoimmune diseases.

Cortical photostimulation was performed by placing the device for photostimulation on the upper walls of the orbits at three points for 2 minutes, for a total of 12 minutes. A second 12-minute exposure was performed after 1 week. Cortical photostimulation was performed in the supine position with eyes closed. The blinds closed and turned off the room lighting, with the exception of a 40 W tungsten light bulb with a lampshade at a distance of 1.5 m from the subject.

In order to prevent light from reaching the retina, the eyes were covered with blinders. The same technique was used with the device turned off for the placebo group. Thanks to the device’s filter system, the emitted light almost does not generate heat, so the subjects could not feel the difference between the device turned on and off.

After the initial phase of 18 days, patients were observed for 4 weeks, while all participants, including the control group, received stimulation lasting 12 minutes (1st and 2nd weeks), 14 minutes (3rd week) and 16 minutes (4th week). The observation included a thorough physical examination by the attending physician to determine the clinical course and possible adverse side effects.

Disease distribution

With autoimmune diseases No autoimmune diseases Rheumatoid arthritis 7 Cancer 2 Systemic lupus erythematosus one Hypothyroidism one Diabetes I 3 Osteoarthritis 2 * Eczema one* No disease 8 Allergies 6 * Psoriasis 2 ** Total: twenty Total: thirteen

* 1 patient suffered from eczema and allergies; another had allergies and osteoarthritis.

** 1 patient suffered from rheumatoid arthritis and psoriasis.

Age and gender distribution

An experience The control Men Women Men Women 1-10 0 one 0 0 18-25 one one 0 0 26-40 3 3 one 2 41-50 one 2 one one 51-60 one one 2 2 61-70 4 one one one 71-80 one 0 0 0

Laboratory tests in all participants were performed before and after stimulation. The first series was carried out 1-2 days before photostimulation. The second series was carried out 18-19 days after the first stimulation. The results were evaluated by determining the number of T cells: CE3. CE4 (helpers), ΟΌ8 (suppressors), ΟΌ4 / ΟΌ8 ratios using the immunofluorescence method based on monoclonal antibodies.

All analyzes were performed by double blind method. For the statistical analysis of serological data, the number of CE3, CE4, 0–8 was determined: the ratio of СО4 / СО8, the percentage of СО3, СО4, СО8, leukocytes and lymphocytes. The significance of changes was evaluated using two-way analysis of variance and Student's t-test.

results

In patients with autoimmune diseases, there was an increase in CO2 by 11.77% (p = 0.01), a decrease in CO2 by 11.32% (p = 0.00100733) and an increase in the ratio of CO2 / CO2 by 26.19% (p = 0 , 00000363) after 2 sessions of cortical photostimulation, that is, for 18-19 days.

Variation analysis showed no relationship between the parameters. 2 significant differences were found between patients with and without autoimmune diseases:

1) the ratio of СО4 / СО8, according to which Ει, ₂₇ = 7.55, p <0.05

2) СО8, according to which Ει, ₂₇ = 6.65, p <0.05.

of 31 patients (64.5%) reported improved sleep and increased energy. This result seems to confirm that stimulation of the orbital region can cause sleep, in which the vagus nerve tone plays a leading role.

During the test and during the observation period, no adverse side effects were observed and there were no reports of them.

Other clinical and serological data on patients with RA are given below. Data for other pathologies of prostate adrenocarcinoma, psoriasis, eczema, allergies, osteoarthritis, hypothyroidism, and diabetes are given above.

Research team

Professor 1. Blaie, Department of Research Methods, School of Medicine, National University of Tucuman (Argentina).

Professor A. Lice, formerly Department of Mathematics, University of Western Ontario (Canada), now Department of Theoretical Biology and Biophysics. Los Alamos National Laboratory (USA). Dr. M. Ροκΐίβΐίοηί, Department of Public Health, Tafi Viejo City, Tucuman (Argentina). Professor M. GhasNagoGG et al. B. Mubble, inventors, London (UK).

Laboratory tests

Analyzes were carried out at the Institute for Clinical Analysis (San Miguel de Tucuman) under the direction of Dr. Μ.Ζ. SNaba be Yesheizhi be B1e1ke.

Subpopulations of lymphocytes in autoimmune diseases

The number of lymphocytes before and after cortical photostimulation

A patient C1) 4C1) 8 SE4,% SE8,% Before After Before After Before After FROM autoimmune diseases one 1,69 1.90 39 38 23 twenty 2 1.70 2.27 41 41 24 eighteen 3 1,56 2,30 36 49 23 21 4 1.72 1.90 43 40 25 21 5 1.70 2.04 40 43 24 21 6 1.75 2.18 42 48 24 22

7 1.65 2.16 38 54 23 25 8 1,56 2.15 39 43 25 twenty nine 1.73 2,50 38 45 22 eighteen 10 1.73 1.91 38 42 22 22 eleven 1.77 2.11 39 38 22 eighteen 12 1,62 1.96 42 51 26 26 thirteen 1.65 2.14 43 47 26 22 Average 1.68 2.12 39.85 44.54 23.77 21.08 Difference 0.44 4.69 -2.69

No autoimmune diseases

14 2.10 1.96 42 45 twenty 23 fifteen 1.83 2.09 42 44 23 21 sixteen 1.95 1.81 39 47 twenty 26 17 1.80 2,30 38 42 21 eighteen eighteen 1.86 2.00 41 38 22 nineteen nineteen 1.65 1.94 33 37 twenty nineteen twenty 1.95 2.05 39 39 twenty nineteen Average 1.88 2.02 39.14 41.71 20.86 20.71 Difference 0.14 2,57 -0.14

Double-blind randomized clinical trial

Rheumatoid arthritis

Methods

Seven patients from Tucuman (Argentina) with RA were selected to participate in a double-blind clinical trial of cortical photostimulation. Subjects were assigned to the active group or to the control group using a random number table. 5 of these 7 people underwent 2 sessions of cortical photostimulation, and in control 2 patients underwent 2 sessions of placebo. The test was carried out by a double blind method, that is, neither the attending physician nor the biochemist knew until the end of the test who received cortical photostimulation in the initial phase of 18 days. The decision to accept all 7 patients into the trial was made prior to randomization.

The test was carried out in accordance with local bioethics requirements. All volunteers gave written consent.

The age in the whole group (3 women, 4 men) ranged from 38 to 66 years. In the experimental group there were 3 men and 2 women, in the control group - 1 man and 1 woman. The subjects of the experimental group had a history of RA lasting 6, 5, 5, 18 years and 6 months, respectively, and the control group had 5 and 7 years.

In each case, the diagnosis was confirmed on the basis of a medical history, physical examination and laboratory tests, in accordance with the classification criteria of the American Association of Rheumatism (AAR), revised in 1987: 7 patients were seropositive for rheumatoid factor (RF); morning rigidity lasting more than 1 hour - 7 people; swelling (arthritis) of 3 or more joints - 7 people; swelling (arthritis) of the joints of the hands - 7 people; symmetrical swelling (arthritis) - 6 people.

RF was determined by latexagglutination (LA) and the Voke-Wadap (BB or ^ aa1et-Bo8e) method. The analysis was considered positive at a dilution of 1: 8 or higher (1: 8 = 1:80;

1:16 = 1: 160 and so on). The first series of analyzes was performed 1-2 days before the first stimulation (or placebo), the second series - after 18 days. The third analysis was performed in another laboratory after 2 weeks.

It should be noted that no patient suffered any acute infection during the trial or observation period. 5 people who received steroids intramuscularly admitted that, along with anti-inflammatory drugs, they sometimes took steroids inside. Since, according to the test protocol, the medication should not be stopped, the attending physician decided not to do a cortisol test.

In active sessions, a photostimulation device was placed on the upper walls of the patients' orbits, sequentially at three points for 2 minutes, for a total of 12 minutes in each case. A second 12-minute light stimulation was performed after a week. The exposure was carried out in a prone position with eyes closed. They closed the blinds and turned off the room lighting, with the exception of one 40-watt tungsten light bulb with a lampshade at a distance of 1.5 m from the subject. As a control, the same technique was used, but with the device turned off.

After the initial phase, patients were observed for 4 weeks. Moreover, all participants, including the control group, were treated weekly. The duration of stimulation was 12 minutes (1st and 2nd weeks), 14 minutes (3rd week) and 16 minutes (4th week). During the observation period, along with a physical examination by the attending physician, a detailed survey was conducted to identify adverse side effects. The significance of the changes was evaluated using binomial analysis with a one-sided criterion.

results

In 4 of the 5 treated subjects, a decrease in the titer of the RF was observed, along with clinical improvement, at the end of the 18-day period, while in the control group, a decrease in the RF was observed without clinical improvement. Over 5 weeks, a significant decrease in the titer of the Russian Federation was noted. The differences between the 1st and 2nd, 2nd and 3rd, and 1st and 3rd analyzes had the following one-sided probability levels:

between 1st and 2nd - not significant (aircraft and explosives); between the 2nd and 3rd - not significant (aircraft and explosives); between 1st and 3rd - p = 0.031 (LA) and p = 0.62 (BB). In the case of one patient, the result could be affected by parallel treatment (homeopathy), begun 9 days after the 1st stimulation. With the exception of this case, the p value for the aircraft does not change, and the p value for the explosive becomes equal to 0.016. These results indicate that changes in serum are clearly apparent after 4 weeks.

Overall, there was a noticeable clinical improvement in 4 out of 7 patients over an average of 5 weeks. All 4 patients showed an increase in grip force and could perform operations requiring precise manual work (drive a car, do a hand wash). Pain during movement in the metacarpophalangial (ICF) and proximal interphalangeal (PMF) joints of the arms and / or legs, elbow, shoulder and knee joints decreased. Of the 2 patients who did not show clinical improvement, one, in addition to developed RA, had a long history of severe osteoarthritis, which led to a permanent loss of performance. Another, self-medicated with homeopathic remedies, showed a marked worsening of symptoms (severe limitation of mobility, acute pain). During the test and during the follow-up period, no adverse side effects of cortical photostimulation were observed and there were never any reports of them.

Research team

Professor 1. ΒίαηοΗί. Research Methods Department, School of Medicine, Tucuman National University (Argentina).

Professor A. Vgiep, formerly - Department of Mathematics. University of Western Ontario (Canada), now Department of Theoretical Biology and Biophysics, Los Alamos National Laboratory (USA).

Dr. M. Ρθ8ίί§1ίοηί, Department of Public Health, Tafi Viejo City, Tucuman (Argentina).

Professor M. Nkasyato GG and Dr. B. Mubbb, inventors, London (UK).

Laboratory tests

The first and second series of analyzes were carried out at the Institute of Clinical Analysis (San Miguel de Tucuman) under the direction of Dr. Μ.Ζ. Syaba be 81shep5ep be B1e1ke.

The third series was conducted by dr. E. Uaka1ko (Tafi Viejo, Tucuman).

Clinical trial - rheumatoid arthritis

Table 1. Decrease in titer of the Russian Federation (for 5 weeks of treatment)

Status LA QC Sta- tus LA QC Sta- tus LA QC 1 L 0 1: 8 L 0 1: 8 L 0 0 2 L 1:32 1:16 L 1:16 1:16 L 1: 8 0 3 L 1:64 1:64 L 1:64 1:64 L 1:32 1:32 4 L 1: 256 1: 128 L 1: 256 1:64 L 1:64 1:64 5 L 1: 256 1:64 L 1: 128 1:64 L 1: 256 1: 128 6K 1:32 1:32 TO 1:16 1:32 TO 1:16 0 7K 1:64 1:64 TO 1:64 1:32 TO 1:32 1:32 Medium her 100.57 53.71 77.71 40 58.28 36.57 Change (%) -2273% -25.52% -42.05% -31.91%

Abbreviations: L - treatment, K - control.

Morning stiffness The number of patients 7 (> 1 h) Number of patients 4 (0.5 h), 3 (> 1 h) Joint swelling Number of points Number of points Decline Wrists 10 5 50.00% PMF hands 49 thirty 38.77% IFF 44 21 52.27% Shoulders 12 8 33.33% Elbows 3 one 66.67% Lap thirteen nine 30.77% PMF toe 52 28 46.15% Total: 183 total: 102 Average: 45.42% Soreness (Ritchie Index) Shoulders Average mark (P, L) 2 Average mark (P, L) 2 Elbows (P, L) 2 (L) 2 (P, L) 1 (L) 0 Wrists (P, L) 2 (L) 2 (P, L) 1 (L) 1 IFF (P, L) 2 (P, L) 1 PMFruk (P, L) 2 (P) 2 (P, L) 1 (P) 2 Lap (P, L) 2 (L) 3 (P, L) 2 (L) 1

Long-term treatment with corticostimulation and observation period Rheumatoid arthritis: patient report No. 1

Patient: woman, age 41 years.

Diagnosis: rheumatoid arthritis since 26 years.

Medicines (local names): Be1Shop, BeLe1 600 mg, IartoShad; Ahasogyb 12 mg and 30 mg per day, Jehkash B12, Me11u1geha1e 7.5 mg per week, 20 mg per day, Stop1eu1 (every 30, 20, 15, 10 and 7 days); Wa1shsh.

Flow. The disease quickly spread to all joints (arms, legs, shoulders, elbows, knees); inflammation and severe pain during movement, stiffness. The patient reported that she became disabled at 36 years old.

Rheumatoid factor in May 1997: LA - 1/256; KK - 1/512

November 1997 Cortical photostimulation (CFS) was launched: 2x12 min per week of July 1998: LA - 1/80; KK - 1/32 October 1998: LA - 1/40; KK - 1/32 January 1999: LA - 1/20; QC is negative.

The clinical course. In the first 3 months of CFS, the patient continued to take all medications (see above). Several times there were relapses of symptoms that stopped after 5 months of CFS. By this time, the patient decided to stop taking the medicine. In November 1998 (1 year after the onset of CFS), the patient claimed that her health condition improved by 80%. Joint inflammation and pain have passed, and headaches and insomnia have also stopped. The patient reported that she was sleeping for 8 hours. Monthly cycles became regular and there were no signs of a previously observed depression. In January 1999, rheumatoid factor tests were negative. All laboratory tests were performed blindly.

Long-term treatment of CFS and the observation period

Table 2. Clinical improvement (after 5 weeks of treatment) Criterion | Before treatment | After treatment |

Rheumatoid arthritis: patient report No. 2 Patient: woman, age 44 g.

Diagnosis: rheumatoid arthritis since 26 years.

Medicines: non-steroidal anti-inflammatory drugs; gold preparations; steroids.

Flow. Within a few years after the initial diagnosis, deformities of the hands (ICF, PMF), legs (PMF), right knee, severe swelling of both knees, right elbow, and shoulders appeared. Severe mobility impairment.

Rheumatoid factor November 1996: LA - negative .; VV - November 1/8, 1996 - January 4, 1997: corticostimulation sessions: 1x12, 14, then 16 min per week of December 1996: aircraft - negative .; VV - 1/8 December 24, 1996: - VV - neg.

The clinical course. 3 weeks after the start of CFS, the patient reported a significant reduction in pain during movement, especially in the knees, shoulders and elbows. For the first time in many years, she could sleep without waking up from pain. At the time when she reported these changes, the patient was taking only хgoh1sat (20 mg per day). In mid-January 1997, there was a straightening of the BMP of the toes — they took on their normal form. At the beginning of 2000, the patient reported that her symptoms were already absent for 3 g.

January 1999: LA - 1/20; BB is negative. All laboratory analyzes from 22/11/96 to 24/12/96 were performed by a double-blind method.

Long-term treatment of CFS and the observation period

Rheumatoid arthritis: patient report No. 3 Patient: male, age 56 years. Diagnosis: rheumatoid arthritis since 45 years. Medicines (local names): AkhasogNb 30 mg per day, EhSHbUpe 8 mg per day, OskhatsFakois (injections).

Flow. Arthritis spread to all joints, with severe pain and swelling of the knees, legs (PMF) and hands (PMF). Serious mobility impairment.

Rheumatoid factor of November 1996: LA - 1/32; BB - 1/32 December 1996 - January 15, 1997 Sessions of cortical photostimulation: 1x12, 14, then 16 min per week of December 1996: LA - 1/16; BB is negative.

January 1997: LA - 1/8; BB - neg.

The clinical course. There was a significant improvement in mobility, especially PMF of the arms and legs. Pain in one shoulder and left knee still continued. There were no CFS sessions after January 15, 1997.

September 1997: LA - 1/16; BB - 1/16 February 1998: LA - 1/8; BB - neg. August 29, 1998: LA - 1/32; BB - 1/16 All laboratory tests from 22/11/96 to

23/12/96 was performed by a double blind method.

Clinical Trial II - AIDS

Methods

A clinical trial was conducted on 8 volunteers with AIDS (<200 T-cells CO4 + / mm ³ ) and 2 with HIV (> 200 T-cells CO4 + / mm ³ ), in which patients received light stimulation 3 times a week for 14 minutes per session for 3-4 weeks using a photostimulation device. The diagnosis was made according to laboratory tests, medical history and physical examination, in accordance with the SES classification system revised in 1993.

The treatment was carried out by placing the device according to the invention on the upper walls of the orbits at three points for the time specified above. The exposure was carried out in a prone position with eyes closed. All room lighting was turned off, with the exception of a 40 W bulb with a lampshade turned away from the subject.

Volunteers (1 woman and 9 men), representing an impartial sample, were from the provinces of Tucuman, Jujuy and Buenos Aires (Argentina). Their age ranged from 25 to 59 years. For ethical reasons, given the critical condition of the patients, the medical team decided not to use the control group. All subjects gave written consent. The test was carried out in accordance with local bioethics requirements.

Two HIV volunteers were included in the trial, taking into account the low number of CE4s, also because a clinical examination showed that they suffered from pneumonia complications caused by Risitosusch salis. Considering the serious condition of the patients and the ethical problems inherent in all experiments in the field of AIDS, as well as the fact that the test itself was carried out without drugs, patients who did not take drugs (4 people) who took 3 types of drugs, including ΑΖΤ ( 4 people), and took only ΑΖΤ (2 people). The decision to continue or stop taking the medicine was made by each subject independently. Of the 4 subjects who did not take the medication, 3 did not take any anti-AIDS drugs for three years before the clinical trial.

The results were assessed by the number of FE4 trimphocytes by immunofluorescence using monoclonal antibodies, by absolute values and by the ΟΌ4 / ΟΌ8 ratio before and after treatment. All T cell determinations after treatment were performed blindly. To assess the reliability of the changes, the Student ΐ criterion and the principle of greatest probability were used.

results

All subjects (100%) showed a significant increase in the number of 0-4 + lymphocytes on average over a period of 22.7 days. Individual values before / after were: 24/213, 40/411, 40/510, 60/616, 80/902, 93/1050, 110/830,

130/795, 304/988, 419/1044. For AIDS patients, the average increase was 879.94%, and for HIV patients - 187.08%. In all cases, except two, a corresponding sharp increase in the ratio 0Ό4 / 0Ό8 was observed. The average value for 8 out of 10 patients (for which complete information is available) is 295.08%. It was distributed as follows:

AIDS - 575.65%, HIV - 125.26%. Two patients showed an inverse ratio of CO2 / SP8 (0.75 and 0.77).

Based on the bilateral Student's 1 criterion, the average increase in the number of лимф4 + lymphocytes after treatment was 605.4%, and the corresponding p value was less than 0.00005. A confidence interval of 95% for the average value, for the whole population, is between 446 and 764. Assuming a normal distribution, the estimate of the average value of the increase in ΟΌ4 + lymphocytes after treatment is most likely to give an impressive number of 605.4%.

Clinical improvement was noted in all 10 subjects within 1-2 weeks. All patients reported a restoration of appetite, increased energy levels and the restoration of a normal sleep cycle after one week of treatment.

Opportunistic infections and their complications, observed in 8 subjects at the beginning of treatment, practically stopped at the end of the 4-week trial period. Of 2 patients with oropharyngeal candidiasis, the pathogen completely disappeared in one case. In another case, he disappeared after 3 weeks and reappeared after a week. This patient suffered from acute adrenal insufficiency. A patient with hepatitis C showed a marked decrease in hepatic enzymes (COT, ORT, alkaline phosphatase and bilirubin) after 3 weeks of treatment. Two patients with complications of pneumonia caused by Rpeišosukyk sapp and two other patients with chronic bronchitis showed a significant improvement over the same period of time. In one case, a relapse of bronchitis occurred during a 4-week follow-up period. Of particular importance is the case of a young man who suffered from meningitis 6 times during the 8 weeks before treatment, and who did not have relapses during the 2-month follow-up period.

A 27-year-old woman who reported that she had not had her period for a whole year before starting treatment began to have menstruation two days after the start of treatment. Other symptoms of illness that have stopped during treatment include malignant generalized lymphadenopathy, oral herpes, peripheral neuropathy, emaciation, and blackout.

During the 4-week follow-up, no adverse side effects of cortical photostimulation were ever observed or reported.

Research team

Professor 1. V1apsy, Department of Research Methods, Faculty of Medicine. National University of Tucuman (Argentina).

Professor A. Vgiep, formerly - Department of Mathematics. University of Western Ontario (Canada), now - Department of Theoretical Biology and Biophysics. Los Alamos National Laboratory (USA).

Dr. E. Ueta and Dr. M. MaPsche. Medical Center, 8shyu1oe 1iY1ayok u Repkyupayoke 1a Aishsh1k1tasyup Rgoush1a1, Tucuman (Argentina).

Professor M. 1kkasjato £$ and dr. B. Maypie, inventors, London (UK).

Laboratory tests

The analyzes were conducted under the supervision of Professor N. Oiieggeh (Faculty of Medicine. National University of Tucuman) at the Center for Parasitology and Immunology (San Miguel de Tucuman) and under the supervision of Dr. Μ.Ζ. SyaPae 81chepkepee B1e1ke at the Institute for Clinical Analysis (San Miguel de Tucuman). Clinical Trials II - AIDS

The treatment period with cortical photostimulation is an average of 22.7 days.

Change in the number of ΟΌ4 + after treatment (on average): AIDS - 879.94%, HIV - 187.08%.

The average increase in the number 0Ό4 + in percent after treatment (bilateral Student's 1-criterion): 605.4%, p <0.00005.

A patient Floor Cart - rast Before treatment After treatment SE4 SE8 S1T4S1E8 SE4 SE8 SMS08 one M 42 24 663 0,03 213 137 1,50 2 F 27 40 200 0.20 411 530 0.77 3 M 25 40 * - - 510 390 1.30 4 M 59 60 530 0.11 616 404 1,52 5 M 28 80 160 0.50 902 450 2.00 6 M 52 93 - - 1050 700 1,50 7 M 26 110 1060 0.10 830 673 1.23 8 M 28 130 600 0.21 795 1060 0.75 nine M 34 304 487 0.62 988 604 1,64 10 M 32 419 326 1.29 1044 396 2.64

* The result of laboratory analysis = 3%.

Long-term treatment of CFS and the observation period

AIDS patient report

Patient: male, age 59 years.

Diagnosis: After several opportunistic infections, AIDS was established in early 1996.

Medications: in February 1996, he started taking ΑΖΤ, from October 1996 to January 1997 - ΑΖΤ + 1pyshau1t + ΌΌΙ. January to May 1997 -ΑΖΤ. From May 1997 to February 1999 - ΑΖΤ + ΌΌΙ (small doses).

Flow. The patient reported emaciation and repeated infections of the respiratory tract. Oropharyngeal candidiasis was established on December 10, 1996.

The number of lymphocytes ΟΌ4 +

05/03/96: 108 CO2 / mm ³

23/05/96: 184 CO2 / mm ³

17/11/96: 60 CO2 / mm ³

Cortical photostimulation (CFS) began on December 6, 1996.

23/12/96: 414 CO2 / mm ³

06/01/97: 616 СО4 / mm ³ Oropharyngeal candidiasis ceased

30/01/97: 699 CO2 / mm ³

... / 02/97: Viral load - 500 000 copies

... / 10/97: Viral load - not detected.

History of CFS

CFS was performed from 6/12/96. Sessions (3x14 min per week) continued on 04/15/97. There were no opportunistic infections for the period from 06/01/97 to February 1999. The patient reported that the number of CE4 + in February 1999 was 650 / mm ³ .

Laboratory analyzes from 23/12/96 and 6/01/97 were performed blindly.

Long-term treatment of CFS and the observation period

Report on a patient with acute lymphoblastic leukemia and hepatitis C

Patient: woman, 56 years old, Argentinean (white), married, 2 children.

Diagnosis: acute lymphoblastic leukemia with a poor prognosis (life expectancy as estimated in February 1998, a maximum of 3 months).

Chemotherapy sessions 20/02/98 - 13/05/98 (used by Syatausha, Agasysh and Ζανοάοκ).

Sessions of cortical photostimulation 19/05/98 - 21/09/98. Normal blood tests on 26/05/98 and no abnormalities in red blood cells on 29/06/98.

Chemotherapy session, one week from 09/21/98. Corticostimulation is interrupted.

Corticostimulation sessions were resumed from 10/10/98 to the third week of December. Normal blood tests on 16/10/98. No abnormalities in red blood cells during the treatment of CFS.

Comments

Despite normal blood tests starting on 05/26/98 and the absence of red blood cell abnormalities on 06/29/98 (after 5 weeks of cortical photostimulation), the oncologist convinced the patient to undergo a new chemotherapy session a week from September 21. Corticostimulation was interrupted.

Cortical photostimulation was resumed in the second week of October 1998. Blood tests returned to normal again on 10/16/98.

The patient contracted hepatitis C through a blood transfusion (positive blood test 10/06/98). In December 1998, hepatic enzymes returned to normal or almost normal levels. Despite this, she was given alpha interferon (3,000,000 U). After the high temperature rose, she went to the hospital, where she received a blood transfusion on 23/12/98, which caused an acute allergic reaction. An antihistamine treatment was carried out, after which the patient fell into a coma. She died of vascular collapse.

All blood tests (in two different laboratories) were performed blindly.

Treatment history

Acute lymphoblastic leukemia. Patient Data

Erythroc Leykots G crete Hemogl Thrombosis Meta Mielo Neutral Eosin Basof Lymph Mono ROE 02/02/98 3060000 3100 29% 9.7 85000 35% 3% 61% one% 3 mm 02/13/98 3080000 4000 27% nine 50,000 one% 4% 23% 0% 0% 46% 02/16/98 2690000 2300 25% 7.9 45000 3% 0% 22% 2% 0% 70% 3% 02/17/98 2870000 1900 24% 72000 52% 0% 2% 43% one% 02/19/98 3070000 1100 26% 61000 48% 0% 0% 52% 0% 02/20/98 2780000 900 22% 7 52000 38% 0% 0% 62% 0% 02/23/98 3190000 200 28% 9.3 5000 0% 0% 0% 0% 0% one hundred% 0% 02/25/98 2480000 200 21% 7 2000 0% 0% 0% 0% 0% one hundred% 0% 02/26/98 2420000 '00 21% 6.8 7500 0% 0% 0% 0% 0% one hundred% 0% 02/27/00 2260000 one hundred nineteen% 6 37500 0% 0% 0% 0% 0% one hundred% 0% 02/28/00 2810000 300 25% 7.9 20000 0% 0% 0% 0% 0% one hundred% 0% 03/02/98 3240000 1400 29% nine 10,000 one% 0% 4% 4% 0% 87% 4% 04/03/98 3560000 4200 32% 9,4 22500 0% 0% 51% 5% 0% 38% 6% 10mm 03/06/98 3380000 9100 thirty% 9.3 125000 one% 0% 70% 4% 0% 21% 4% 09/03/98 3720000 8300 33% 10 205000 one% 0% 63% 2% 0% thirty% 4% 12/03/98 3710000 3900 32% 10.8 330,000 2% 3% 70% 0% 0% 21% 3% 6 mm 03/18/98 3410000 4400 28% 10.1 520000 75% 0% 0% twenty% 5% 9 mm 03/23/98 3320000 6100 29% 9.2 290000 0% 0% 91% 0% 0% 8% one% 03/26/98 3010000 2300 25% 8.8 210000 76% one% 0% twenty% 3% 16mm 03/30/98 2350000 400 nineteen% 6.8 32000 eleven% 0% 0% 85% 4% 20mm 04/03/98 3070000 3600 28% 8.3 35,000 0% 0% 77% 0% 0% twenty% 3% 04/06/98 2930000 6200 24% 8.5 120,000 4% 70% nine% 0% 12% 5% 15mm 04/14/98 3660000 5200 31% 10.5 390000 2% 3% 48% 0% one% 33% 10% 10mm 04/21/98 3,400,000 5050 29% 10,4 320,000 79% one% 0% twenty% 0%

04/24/98 3610000 4100 31% 10.9 330,000 63% 0% 0% 22% fifteen% 04/27/98 3,600,000 3900 32% 10.8 310000 78% 0% 0% nineteen% 3% 04/05/98 3,600,000 12400 33% 11.2 170000 2% 93% 0% 0% 3% 2% 4mm 05/05/98 3650000 800 33% 11.20% 78000 40% 0% 0% 60% 0% 5 mm 11/05/98 2850000 300 24.50% 8.8 21000 one% 0% 0% 99% 0% 26mm 05/13/98 2420000 300 21% 7 5000 0% 0% 0% 0% 0% one hundred% 0% 35 mm 05/15/98 2820000 1200 25% 7.4 75,000 2% 0% thirty% 0% 0% 66% 2% 16 mm 05/16/98 3430000 5400 31% 9.9 90,000 2% 0% 84% 0% 0% 12% 2% 15mm 05/19/98 3340000 21100 29% 10.1 215000 6% 3% 80% 2% 0% 4% 4% 15 mm

Beginning of cortical photostimulation: 05/19/98. Treatment: 3x12 minutes per week

Erythroc Leykots G crete Hemogl Thrombosis Meta Mielo Neutral Eosin Basof Lymph Mono ROE 05/22/98 3760000 6700 34% 10.5 205000 2% 0% 61% 4% 0% 24% nine% 9 mm 05/26/98 3460000 3400 thirty% 10.7 310000 59% 0% one% 25% fifteen% 10mm 06/06/98 3650000 3600 33% 11.3 245000 2% 79% 0% 0% thirteen% 6% 9 mm 09/06/98 3660000 3700 32% 10,4 215000 71% 0% 2% sixteen% eleven% - 06/18/98 4040000 4700 37% 12.6 260,000 2% 79% 0% 0% 12% 7% 4 mm 06/29/98 4060000 5200 37% 11.8 210000 0% 0% 68% 0% 0% 25% 4% 5 mm 07/13/98 4590000 5800 41% thirteen 245000 0% 0% 68% 2% 0% 27% 3% 4mm 07/27/98 4580000 4900 41% 12.8 180,000 0% 0% 61% 0% 0% 34% 5% - 05/08/98 4470000 3800 40% thirteen 175,000 0% 0% 60% 0% 0% 35% 5% - 11/08/98 4350000 4300 40% 12.7 190000 0% 0% 70% one% 0% twenty% 7% - 08/24/98 4470000 5000 40% thirteen 245000 0% 0% 65% 0% 0% 28% 4% 4mm 09/09/98 4420000 5800 39% 12.9 215000 0% 0% 64% 0% 0% thirty% 4% 4 mm 09/11/98 3,900,000 4100 35% 12.3 265000 63% 0% 0% 32% 5% - 09/21/98 3650000 3300 33% 10,4 160,000 0% 0% 73% one% 0% 24% 2% 7mm Chemotherapy session. Corticostimulation interrupted 09/25/98 3310000 800 29% 9.6 45000 0% 0% fifty% 0% 0% 49% one% - 09/28/98 2780000 600 24% 8 15,000 0% 0% 24% 0% 0% 75% one% 13mm 09/30/98 2790000 500 25% 7.8 25,000 0% 0% 5% 0% 0% 95% 0% 17mm 01/10/98 2720000 2400 24% 7.9 25,000 0% 0% 32% 0% 0% 62% 6% 12mm 02/10/98 2760000 5700 24% 8 30000 0% 0% 72% one% 0% twenty% 7% 15mm 05/10/98 3190000 32600 29% 9,4 105000 one% 0% 93% 0% 0% 4% 2% 12mm Cork sessions ur stimulation resumed 10/16/98 3390000 4400 thirty% 9.9 320,000 0.00% 0% 55% one% 0% 37% 7% 9 mm 10/30/98 4,240,000 5300 38% 12.5 250000 0% 0% 65% 0% 0% 26% nine% - 17/11/98 4420000 4400 39% 12.6 125000 0% 0% 66% 0% 0% thirty% 4% - 11/30/98 4150000 4800 37% 12 180,000 0% 0% 68% 0% 0% 28% 4% -

Acute lymphoblastic leukemia. Patient Report (Observations) 02/02/98 anisocytosis 02/13/98 erythroblasts anisocytosis hypochromia 02/16/98 hypochromia hypochromia anisochromia macrocytosis 02/17/98 hypochromia anisocytosis 02/19/98 hypochromia anisocytosis microcytosis anisochromia 02/20/98 hypochromia anisocytosis poikilocytosis 03/06/98 hyperbasoph. mononuclear 09/03/98 hypochromia anisochromia macro thrombocytes 12/03/98 hypochromia anisocytosis microcytosis 03/18/98 hypochromia anisocytosis microcytosis 03/26/98 hypochromia anisocytosis 03/30/98 hypochromia anisocytosis 04/06/98 hypochromia anisocytosis 04/14/98 hypochromia anisocytosis erythroblasts hypersegment, neutrophils 04/21/98 hypochromia anisocytosis 04/24/98 hypochromia anisocytosis 04/27/98 hypochromia anisocytosis 05/05/98 hypochromia anisocytosis 11/05/98 hypochromia anisocytosis 05/15/98 hypochromia 05/19/98 hypochromia anisocytosis erythroblasts Start of the cortical photo studio: 05/19/98. Treatment: 3x12 min / week 05/22/98 anisochromia 05/26/98 hypochromia anisocytosis erythroblasts 06/06/98 hypochromia anisocytosis

09/06/98 hypochromia anisocytosis 06/18/98 hypochromia anisocytosis 06/29/98 no deviations 07/13/98 no deviations 07/27/98 no deviations 05/08/98 no deviations 11/08/98 no deviations 08/24/98 no deviations 09/09/98 no deviations 09/11/98 09/21/98 no deviations no deviations Chemotherapy session. Corticostimulation interrupted 09/25/98 no deviations 09/28/98 no deviations 09/30/98 no deviations 01/10/98 no deviations 02/10/98 no deviations 05/10/98 macro thrombocytes Corticostimulation sessions resumed 10/16/98 no deviations 10/30/98 no deviations 17/11/98 no deviations 11/30/98 no deviations

Hepatitis C. Patient data

ian Bilirubin COT ORT Click. Phosphate. Co1 COT 5'nucleotidase 02/16/98 199 02/23/98 129 02/25/98 165 1.17 thirteen 21

02/28/98 181 1.13 29th 03/02/98 220 0.97 thirty 04/03/98 1,04 03/06/98 271 29th 03/23/98 60 28 04/03/98 319 34 79 04/21/98 146 31 42 04/24/98 7.9 04/27/98 137 36 46 5036 04/05/98 13,2 05/05/98 10.3 11/05/98 109 36 57

Beginning of cortical photostimulation: 05/19/98. Treatment: 3x12 min / week

06/06/98 174 49 56 39 09/06/98 243 246 324 10/06/98 1.15 12800 06/16/98 280 390 270 06/18/98 10.3 74 106 46 4310 146 sixteen 06/29/98 0.94 237 400 361 7821 320 26,4 07/13/98 1.09 296 556 472 8126 367 30.7 07/27/98 363 227 431 299 08/25/98 435 212 393 395 11/08/98 08/24/98 1,04 107 249 403 8711 170 40.5 09/09/98 118 200 315 8513 98 38,4 09/21/98 83 180 298 7817 95 18.6 09/28/98 61 143 286 7067 76 20,4 01/10/98 51 105 346 6147 62 30.3 05/10/98 42 73 505 6120 77 45,2 10/16/98 49 74 315 7460 62 18.3 10/30/98 336 81 127 318 8310 17/11/98 346 49 113 11/30/98 27 37 38

CLAIM

Claims (8)

CLAIM 1. A method for the treatment of neuro-immunoendocrine disorders, including photostimulation of the orbital region of the cerebral cortex sequentially through at least three adjacent points of the upper wall of each eye socket with light with wavelengths of 350-400 and 750-800 nm, and the exposure time for each point is not less than two minutes. 2. The method according to claim 1, in which the disorders to be treated include allergies, in particular respiratory infections, immunodeficiency, cancer, systemic lupus erythematosus, eczema, psoriasis, thyroid disease, viral syndromes, pathologies associated with neuro-immunoendocrine disorders, hypertension, chronic pharyngitis, rheumatoid arthritis. 3. The device for implementing the method according to claim 1, containing light-emitting means providing light with wavelengths of 350-400 and 750-800 nm. 4. The device according to claim 3, in which the light emitting means is a light source of low power. 5. The device according to claim 4, in which the light source is a medical lamp of low power. 6. The device according to any one of claims 1 to 3, in which the light-emitting means includes at least 2 lenses, each of which is equipped with quartz glass and a lens. 5. The device according to claim 5, in which the light emitting means includes a filter in front of each lens, transmitting light with a wavelength at 350-400 and 750-800 nm. 6. The device according to claim 5, in which the filter is equipped with a diffuser. 7. The device according to any one of claims 1 to 6, further comprising an output power regulator for changing the voltage / current supplied to the light emitting means, and an indicator showing the voltage / power of the supplied current. 8. The device according to claim 1, containing programmable functions. Clinical trial II - AIDS CE4 + lymphocyte count (before and after) The treatment period with cortical photostimulation is an average of 22.7 days. The average changes after treatment with cortical photostimulation: AIDS - 879.94%, HIV - 187.08%.